IV fosfomycin for serious bacterial infections
Part of Bones, joints & muscles, Brain & nervous system, Heart & circulation, Infections, Kidney & urinary, Lungs & breathing, Skin, Women’s health & pregnancy clinical trials.
This trial studies whether IV (through a vein) fosfomycin can treat severe bacterial infections in adults. It may help people whose infection is covered by the standard fosfomycin use and who need hospital-level care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your doctor needs to plan treatment with IV fosfomycin (through a vein) as the standard recommended use allows.
- Your infection must be one of the types listed, such as bone infection (osteomyelitis), complicated urine infection, hospital-acquired lung infection, bacterial meningitis/brain infections, bloodstream infection/sepsis, skin/soft tissue infection, or infection of the heart lining/valves (endocarditis).
- You (or your legally responsible representative) must be able to give written informed consent.
- You must not have an allergy to fosfomycin.
- You must not be in another interventional drug trial, and your situation must not be end-stage/comfort-only care (including “do not resuscitate” orders).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether fosfomycin works better than the usual treatment for children with urine infections caused by antibiotic-resistant germs. It may help by using an antibiotic choice that can still work when common oral options may fail.
This study looks at how well the antibiotic fosfomycin works for bacterial infections in patients who received it in the hospital. It may help doctors understand the best ways to use this medicine.
This study tests a single dose of fosfomycin, an antibiotic, compared to a placebo for treating urinary tract infections in men. The goal is to see if it helps relieve symptoms and clear the infection better than no active treatment.
This trial tests a new drug, Fosmanogepix, for treating serious mold infections that are hard to treat with current medicines. It may be an option for people with limited treatment choices.
This study tests whether combining two antibiotics (ceftazidime and fosfomycin) works better than ceftazidime alone for hospitalized adults with serious bacterial infections. If you have a severe infection thought to be caused by Gram-negative bacteria, this trial may offer a new treatment option.
This trial looks at how well two antibiotics, ceftazidime-avibactam and fosfomycin, work together to treat infections caused by highly resistant bacteria called CRE. It may help find the best way to use these medicines.
Hear when a new Bacterial Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.